E. Ohman J:or Asset Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

E. Ohman J:or Asset Management’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-145,921	Closed	-$1.68M	–	426
2022 Q4	$1.68M	Buy	145,921 +49,157	+51%	+$613K	0.07%	164
2022 Q3	$1.22M	Sell	96,764 -51,995	-35%	-$669K	0.06%	205
2022 Q2	$1.57M	Buy	148,759 +50,000	+51%	+$516K	0.07%	170
2022 Q1	$1.61M	Sell	98,759 -86,141	-47%	-$1.38M	0.05%	203
2021 Q4	$2.56M	Buy	184,900 +53,800	+41%	+$712K	0.07%	161
2021 Q3	$1.88M	Buy	131,100 +7,000	+6%	+$110K	0.06%	188
2021 Q2	$1.96M	Sell	124,100 -20,000	-14%	-$272K	0.06%	183
2021 Q1	$1.47M	Buy	144,100 +16,000	+12%	+$165K	0.05%	203
2020 Q4	$954K	Buy	+128,100	New	+$660K	0.04%	232

Other funds holding BCRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

E. Ohman J:or Asset Management's BCRX Position: Q1 2023 in Review

E. Ohman J:or Asset Management sold out of BioCryst Pharmaceuticals (BCRX) in Q1 2023, closing a stake of 145,921 shares — an estimated $1.68M sold.

E. Ohman J:or Asset Management first reported a position in BCRX in Q4 2020 and held it in 9 quarters. The position peaked at $2.56M in Q4 2021. 241 funds tracked by Wall St. Rank hold BCRX as of Q1 2023.

E. Ohman J:or Asset Management reported no remaining BioCryst Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
E. Ohman J:or Asset Management sold 145,921 BioCryst Pharmaceuticals shares in Q1 2023, an estimated $1.68M.
E. Ohman J:or Asset Management first reported a position in BioCryst Pharmaceuticals in Q4 2020 and held it in 9 quarters.
E. Ohman J:or Asset Management's BioCryst Pharmaceuticals position peaked at $2.56M in Q4 2021.
241 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2023.

Based on E. Ohman J:or Asset Management's 13F filing for Q1 2023, filed 5 Apr 2024.